Alivus Life Sciences Limited (ALIVUS) Share Price
NSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE03Q201024
Key metrics
- Market Cap
- ₹17,419 Cr
- P/E Ratio
- 28.92
- EPS
- 49.06
- Book Value
- 271.49
- P/B Ratio
- 5.22
- ROE
- 16.94%
- ROCE
- 21.3%
- Debt / Equity
- 0.02
- Net Margin
- 22.12%
- Revenue Growth
- 6.91%
- Profit Growth
- 16.24%
- Dividend Yield
- 0.35%
- 52W High
- ₹1,493.80
- 52W Low
- ₹819.00
- Market Cap Band
- mid cap
- Face Value
- 2
Ratios computed from the annual results period ending 2026-03-31.
About Alivus Life Sciences Limited
Alivus Life Sciences Limited develops and manufactures active pharmaceutical ingredients in India, the United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China, and Australia. It offers various APIs, such as amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, solifenacin, atovaquone, etoricoxib, dapagliflozin, and sitagliptin for therapeutic areas, including cardiovascular, central nervous system, diabetes, oncology, urology, and pain management, as well as anti-fungal, anti-histaminic, anti-acne, anti-emetics immunomodulators, anti-ulceratives, immunosuppressant, respiratory agent, ophthalmologic agent, anti-spasmodic, and urology. The company also provides contract development and manufacturing comprising process development, analytical development and support, and API and intermediate manufacturing; and research and development, intellectual property, quality and compliance, customer experience, regulatory support. In addition, it exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 and is based in Mumbai, India. Alivus Life Sciences Limited operates as a subsidiary of Nirma Limited.
- Headquarters
- Mumbai, India
- Employees
- 2,272
- Promoter Holding
- 76.08%
The full Alivus Life Sciences Limited analysis
Create a free account to open the complete ALIVUS deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.